Novye ul'tradlitel'nye beta-2-agonisty v terapii khronicheskoy obstruktivnoy bolezni legkikh


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Bronchodilators occupy a central place in the pharmacotherapy of chronic obstructive pulmonary disease (COPD). All new medicines proposed in recent years are the drugs with broncholytic action (long acting β 2-agonists, long-acting mucolytics, phosphodiesterase selective inhibitors). The use of bronchodilators allows to reduce the severity of dyspnea and other symptoms, and increases the exercise tolerance approximately in 40 % of patients with COPD. Indacaterol is a new representative of ultra-long-acting β 2-agonist with a rapid action. The main feature of the drug is its extremely high affinity to lipid rafts of the cell membrane; therefore, indacaterol able to act about 24 hours, allowing to use it once a day. In addition, indacaterol has a high cardiosafety profile.

全文:

受限制的访问

作者简介

N. Knyazheskaya

参考

  1. Чучалин А.Г. и др. Практические рекомендации по диагностике, лечению, профилактике ХОБЛ. М., 2005.
  2. Global Initiative for Chronic Obstructive Lung Disease. 2009. www.goldcopd.org.
  3. European Lung Foundation. COPD Burden in Europe. 2009 www.european-lung-foundation.org.
  4. Лещенко И.В. Ключевые вопросы ранней терапии хронической обструктивной болезни легких // Consilium Medicum 2008. Т. 10. №10.
  5. Lopez A.D., Shibuya K., Rao C., et al. Chronic Obstructive Lung Disease: current burden and future projections. Eur Respir J 2006; 27(1):188-207.
  6. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498-504.
  7. Архипов В.В. Фармакоэкономический подход к терапии хронической обструктивной болезни легких // Consilium Medicum 2010. Т.12. № 3.
  8. Респираторная Медицина. Руководство / Под редакцией А.Г. Чучалина. М., 2007. Т. 1. 626 с.
  9. Anthonisen N.R., Connett J.E., Murray R.P. and The Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-79.
  10. Чучалин А.Г. Система оксиданты и антиоксиданты и пути коррекции // Пульмунология 2004. № 4. С. 111-15.
  11. Соодаева С.К. Роль свободнорадикального окисления в патогенезе ХОБЛ // Атмосфера. Пульмонология и аллергология 2000. № 5. С. 27-31.
  12. Rytila P., Rehn T., Humets H., et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006;28(7):69.
  13. Yigla M., Berkovich Y., Nagler R.M. Oxidative stress indices in COPD-Broncho-alveolar lavage and salivary analysis. Arch Oral Biol 2007; 52(1):36-43.
  14. Siafakas N.M., Vermeire P., Pride N.B., et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398-20.
  15. Пресс-выпуск ВЦИОМ № 1234 от 29 мая 2009 г.
  16. Чучалин А.Г. и др. Качество жизни больных хронической обструктивной болезнью легких в России: результаты многоцентрового популяционного исследования ИКАР-ХОБЛ // Пульмонология 2004. № 1. С. 93-102.
  17. www. who.int/entity/mediacentre/news/ releases/2007/pr47/ru/-44k
  18. Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sci 1993.
  19. Dahl R., Greefhost LARM., Nowak D., et al. Inhaled formoterol dry in cronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84.
  20. Сazzola M., et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998;114(2):411-15.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012